CURRICULUM VITAE Revised: May 2011 BAXTER DELWORTH MONTGOMERY, MD PRESENT TITLES: Clinical Assistant Professor The University of Texas Health Science Center Department of Medicine Division of Cardiology/Clinical Cardiac Electrophysiology President and CEO Houston Associates of Cardiovascular Medicine, PA. (1997- Present) Executive Director The Johnsie and Aubary Montgomery Institute of Medical Education and Research (a 501 (c) 3 nonprofit organization) BIRTHDATE: February 21, 1964 BIRTH PLACE: Houston, Texas United States of America OFFICE ADDRESS: 10480 South Main St. Houston, Texas 77025 (713) 599-1144 phone (713) 599-1199 fax bmontgomery@drbaxtermontgomery.com UNDERGRADUATE EDUCATION: William Marsh Rice University Houston, Texas Bachelor’s Degree in Biochemistry (1986)
GRADUATE EDUCATION: The University of Texas Medical Branch at Galveston Galveston, Texas Doctor of Medicine RESIDENCY: Baylor College of Medicine Houston, Texas Internal Medicine FELLOWSHIP: The University of Texas Health Science Center at Houston Houston, Texas Cardiovascular Diseases Clinical Cardiac Electrophysiology
CERTIFICATION: Diplomate of the American Board of Internal Medicine, Cardiovascular Diseases Diplomate of the American Board of Internal Medicine, Clinical Cardiac Electrophysiology LICENSURE: Texas State Board of Medical Examiners (Since Permit Number H9549
HOSPITAL APPOINTMENTS:
Attending Physician Memorial Hermann Hospital – The Texas Medical Center
Houston, Texas Attending Physician The Heart and Vascular Institute Memorial Hermann Hospital – The Texas Medical Center
Teaching Faculty for Cardiology Fellows and Clinical Advanced Nurse Practitioners The Heart and Vascular Institute Memorial Hermann Hospital – Texas Medical Center 1997 – Present Cardiovascular Disease Lecturer GlaxoSmithKline, Inc. 2000 – Present Cardiovascular Disease Lecturer Novartis, Inc. 2006 – Present Cardiovascular Disease Lecturer Boston Scientific, Inc. 2006 – Present Co-Director and Lecturing Faculty Cardiology Concepts for Non-Cardiologists (An Annual Houston Area Educational Symposium) JAM Institute, Inc. 2006 – 2008 Steering Committee Member and Lecturing Faculty Close the Gap Boston Scientific, Inc. 2006 – Present
RESEARCH: CLINICAL STUDIES: ALLHAT: Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial. ALLHAT was a blinded, randomized trial that investigated the relative efficacy of different classes of antihypertensive agents in reducing stroke, illness and death from cardiovascular diseases. A subgroup of patients with hyperlipidemia was randomized comparing Pravastatin compared to usual care. A Houston Site – Principal Investigator (1998) INVEST: The International Verapamil SR/ Trandolapril Study. INVEST was a randomized controlled clinical trial comparing a calcium antagonist treatment strategy (Isoptin® SR) with a
non calcium antagonist treatment strategy for the control of hypertension in a primary care coronary artery disease patient population. A Houston Site – Principal Investigator (1998) INVEST SUB-STUDY: This study was a sub- study of the INVEST patient population designed to evaluate the impact of genetic differences on pharmacokinetics. A Houston Site – Principal Investigator (2000) The Safety and Efficacy of PNU-182716 Versus Rosiglitazone: This was a one-year, randomized, double blind, parallel group, and active comparator study. A Houston Site – Principal Investigator (2000) FACTOR: Fenofibrate and Cerivastatin Trial Optimizing Response. FACTOR was a multicenter, randomized, double blind, placebo controlled, parallel group, study of the safety and efficacy of Cerivastatin in combination with Fenofibrate compared to Cerivastatin alone, Fenofibrate alone and placebo in a population of Type 2 Diabetic Men and Women. Grant Sponsor – Bayer 2001 A Houston Site – Principal Investigator ADHERE: ADHERE was a national registry of patients admitted to hospitals with acute decompensated congestive heart failure. A Houston Site – Principal Investigator (2001) STELID TM AND STELIX TM LEADS STUDY: This study was a safety and efficacy study of steroid-eluting cardiac pacing leads. Grant Sponsor – Ella Medical2002 A Houston Site – Principal Investigator ARRHYTHMIA PATHWAY STUDY: This was a patient registry study designed to assess the efficacy of a clinical algorithm for identifying and assessing patients at risk of sudden cardiac arrest. Grant Sponsor – Medtronic, Inc. 2002 A Houston Site – Principal Investigator RAPIDO CATHETER STUDY: This study was designed to evaluate the efficacy of a left ventricular defibrillator-pacemaker lead delivery system. Grant Sponsor – Guidant, Inc. 2003 A Houston Site – Principal Investigator
PROTOS HEART RATE DISTRIBUTION STUDY: This was a clinical study designed to compare the heart rate distribution in patients undergoing pacemaker implants requiring heart rate response therapy. This study compared the heart rate distribution of accelerometer rate response therapy to the BIOTRONIK Closed Loop System therapy. Grant Sponsor – Biotronik, Inc. 2003 A Houston Site – Principal Investigator CSPP100A2404- A 54 week, randomized, double- blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of Aliskiren (300 mg) compared to Ramipril (10 mg) in patients with essential hypertension. Sponsored by Novartis, since April 4, 2008. CSPP100AUS03-
Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ versus Amlodipine in African American Patients with Stage 2 Hypertension. Sponsored by Novartis, since August 2008. CSPP100A2409- An 8 week randomized, double- blind, parallel-group, multicenter, active-controlled dose escalation study to evaluate the efficacy and safety of Aliskiren HCTZ (300/25 MG) compared to Amlodipine (10 mg) in patients with satage 2 systolic hypertension and diabetes mellitus. Sponsored by Novartis, since December 2008. SPA100AUS01-
Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of
Aliskiren Administered in Combination with Amlodipine (150/5mg, 300/10 mg) versus Amlodipine alone (5 mg, 10 mg) in African American patients with stage 2 hypertension. Sponsored by Novartis, since February 2009. CLAF237B2201- A multicenter, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modifies release (MR) as monotherapy in patients with type 2 diabetes. Sponsored by Novartis, since February 2009. CLAF237B2224- A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes. Sponsored by Novartis, since February 2009. BASIC RESEARCH: Increased Frequency of the Deletion Allele of the ACE Gene in African-Americans Compared to Caucasians. This study evaluated the prevalence of the deletion allele of the ACE gene in a population of African Americans compared to Caucasians. The findings were presented at the annual meeting of the American College of Cardiology in March of 1996. Determination of the effect of Calcium infusion on CGRP mRNA Production. A pilot study investigating a possible mechanism by which calcium supplementation may increase CGRP (Calcitonin gene-related peptide, a potent peripheral vasodilator) content in afferent neurons of Sprague Dawley rats, 1990. The Adenine Nucleotide Pool-Size of Heart Mitochondria is Regulated by the ADP/ATP Translocase. Abstract presented at the 29th Annual National Student Research Forum, University of Texas Medical Branch, Galveston Texas, April 6-8, 1988. Regulation of the Adenine Nucleotide Pool-Size of Heart Mitochondria by the ADP/ATP Translocase. Abstract and poster presented at the Galveston-Houston Conference for Cardiovascular Research, Univ. of Texas, Medical Branch, Galveston, TX, February 26, 1988. Rapid Separation of Mitochondria from Extra- mitochondrial Space Applied to Rat Heart Mitochondria. An abstract presented at an NIH sponsored student research poster session, Univ. of Texas Medical Branch, Galveston, TX, June 17, 1987.
PUBLICATIONS:
Montgomery, Baxter D: The Food Prescription for Better Health, Houston: Delworth Publishing, 2011 Doyle, N.M., Monga, M., Montgomery, B., Dougherty, A.H.: Arrhythmogenic right ventricular cardiomyopathy with implantable cardioverter defibrillator placement in pregnancy. J Mat Fetal Neo Med 18:141-4, 2005 Baxter D. Montgomery, MD, Elizabeth A. Putnam, Ph.D., John Reveille, MD, Dianna M. Milewicz. MD, Ph.D.: Increased Frequency of the Deletion Allele of the ACE Gene in African- Americans Compared to Caucasians. (Abstract) J. American College of Cardiology March, 1996 Montgomery, B, D., A Review of Microanatony for Medical Students, 1987, chapter 1-8.
CLINICAL PRESENTATIONS:
Clinical Concepts for Non Cardiologists, Director and Faculty. An educational symposium held for primary care and other non-cardiology specialists in the Houston area. October, 2006. Clinical Concepts for Non Cardiologists, Co-Director and Faculty. An educational symposium
held for primary care and other non-cardiology specialists in the Houston area. October, 2007. Patients at Risk for Sudden Cardiac Arrest Dinner Symposium at the Houston Forum June, 2007 January, 2006
PROFESSIONAL APPOINTMENTS:
Clinical Assistant Professor of Medicine, University of Texas Health Science Center – Houston 1996 – Present
Steering Committee Member, Boston Scientific Close the Gap Initiative 2005 – Present
Scientific/Medical Board of Advisors, Nutritional Excellence, Inc. 2007 – Present
Medical Board of Directors, Twelve Oaks Medical Center Independent Physician’s Association 2005 – Present
Medical Executive Committee (Twelve Oaks Hospital), Member at Large 2002 – 2006
Patient Safety Committee (Twelve Oaks Hospital), Chairman 2002 – 2004
Physician Peer Review Committee (Twelve Oaks Hospital) 2002 – 2005
Medical Director, SCCI (Specialized Complex Care) Hospital, 2003 – 2005
Physician Relation Council Advisory Board, Unicare, 2002 – 2004
CLINICAL INTERESTS:
Cardiac Pacing and Electrophysiology Sudden Cardiac Arrest
Diastolic and Systolic Heart Failure Hypertensive Heart Disease Cardiovascular Exercise Physiology
PROFESSIONAL ASSOCIATIONS:
American College of Cardiology (Elected as Fellow
Heart Rhythm Society (North American Society of
HONORS AND AWARDS
Cumulative evaluation of “Superior” performance
by senior house staff and faculty during first year of residency (Baylor College of Medicine), 1990
Kempner Award (University of TX Medical
Academic Scholarship (University of TX Medical
Franz Brotzen Outstanding Senior Award (Rice
Jones College Service Award (Rice University)
ACTIVITIES:
Délibération Délibération de la Commission de régulation de l’énergie du 11 décembre 2013 portant décision d’approbation du programme d’investissements de RTE pour 2014 Participaient à la séance : Olivier CHALLAN BELVAL, Hélène GASSIN et Jean-Pierre SOTURA, commissaires En application des dispositions du 2° de l’article L. 134-3 du code de l’énergie, le gestionnai
BIOMIST® 4+4 ULV www.clarkemosquito.com For Use Outdoors as an Ultra-Low Volume (ULV) Application to Control Adult Mosquitoes in Residential andRecreational Areas. This product is highly toxic to bees exposed to direct treatment on blooming crops orPermethrin (3-Phenoxyphenyl) methyl (+/-) cis,weeds. Do not apply this product or allow it to drift to blooming crops or weeds whiletrans-3-